Why the study?
While bleeding is a common side effect of direct oral anticoagulants, spontaneous hemorrhagic pericardial effusions are not seen frequently.
Highlights a rare but severe complication of spontaneous hemorrhagic pericardial effusion associated with apixaban use.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible early apixaban-associated hemorrhagic effusion; hypothesis-generating case that leaves causality and incidence open.
Direct oral anticoagulants (DOACs) have revolutionized therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation. These medications are generally well tolerated and are not associated with the inconvenience of repeat international normalized ratio (INR) checks. While bleeding in general is a common side effect associated with DOACs, especially from a gastrointestinal source, spontaneous hemorrhagic pericardial effusions are not seen frequently. Herein, we present a case of a patient who developed a hemorrhagic pericardial effusion three days after the initiation of apixaban. We also summarize the current data that is available showing this side effect and highlight an important risk factor that may predispose patients to this complication.
No takes yet. Share an insight, caveat, or question.
Nasir et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: